The innate immune system is the body’s first line of defense against a range of pathogens, and is exceedingly adept at killing fungal pathogens. Biothera’s Pharmaceutical Group is developing compounds that work synergistically with monoclonal antibodies to engage and direct this fungal killing mechanism against cancer cells. Clinical and preclinical research demonstrates the effectiveness of this platform technology to significantly improve outcomes in a wide range of cancers. The company’s lead drug candidate, Imprime PGG®, is currently in multiple Phase 2 clinical trials and a Phase 2-3 trial for colorectal cancer.
Biothera has a robust pharmaceutical development program that includes advanced clinical trials to treat colorectal cancer, non small cell lung cancer and chronic lymphocytic leukemia. For more information, including trial locations and participation requirements, go to clinical trials.
A study published as the cover story in April 2011 issue of the journal Nature features Biothera’s beta glucans and new discoveries about how these unique immunodulating compounds prime the innate immune system to protect the body. “This research demonstrates that the structure of beta glucans matters,” said William Grossman, M.D., Ph.D., Biothera senior vice president of Research & Development. “Even slight molecular differences in beta glucans affect the signaling pathways used to induce different killing mechanisms. These data expand on our previous research showing that some of our other beta glucan structures bind to CR3, inducing separate and unique mechanisms.” News Release
Biothera's pharmaceutical business has been profiled recently in industry publications targeting investors and potential licensing partners.
This three-minute animation illustrates how Biothera's Imprime PGG® works inside the body to prime innate immune cells to recognize and kill a wide range of pathogens and cancer cells.